1525 Superior Avenue, Suite 200
Newport Beach, CA 92663
Phone (949) 650-0506
Fax (949) 999-8126

Receive our newsletter
  Home  
  Our Team  
  Patient Info  
  Contact Us  

News for Healthier Living

Stelexis BioSciences Announces Positive Phase 1 Data for Eganelisib in Relapsed/Refractory AML and Higher-Risk MDS in an Oral Presentation at ASCO 2026

The improved overall survival in patients with high expression of PI3K-gamma in this Phase 1 study is internally consistent with the observed responses and is externally validated by the TCGA database, which suggests a poor prognosis for patients with high expression of PI3K-gamma. Eganelisib generated a striking efficacy signal while demonstrating a favorable safety and tolerability profile in this Phase 1 study.

June 2, 2026


June 9 2026

June 8 2026

June 7 2026

June 5 2026

June 4 2026

June 3 2026

June 2 2026

June 1 2026

May 31 2026

May 30 2026

May 29 2026

May 28 2026

May 27 2026

May 26 2026